Related references
Note: Only part of the references are listed.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Matthew Warrender-Sparkes et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Matthew Warrender-Sparkes et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis
Nikolai Pfender et al.
NEUROLOGY (2015)
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
Ludwig Kappos et al.
NEUROLOGY (2015)
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod Risk Assessment and Consensus Recommendations for Management
Ann M. Arvin et al.
JAMA NEUROLOGY (2015)
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
Anna He et al.
JAMA NEUROLOGY (2015)
Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis
Miriam J. Smith et al.
NEUROLOGY (2015)
Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
John Camm et al.
AMERICAN HEART JOURNAL (2014)
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2014)
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
Ralf Gold et al.
JOURNAL OF NEUROLOGY (2014)
Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study
Cecilie Jacobsen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model
Daniel C. Anthony et al.
NEUROPHARMACOLOGY (2014)
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
Niklas Bergvall et al.
PLOS ONE (2014)
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
Nele Claes et al.
PLOS ONE (2014)
Fingolimod for the treatment of neurological diseases—state of play and future perspectives
Robert Brunkhorst et al.
Frontiers in Cellular Neuroscience (2014)
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis
Niklas Bergvall et al.
JOURNAL OF MEDICAL ECONOMICS (2014)
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient Out Comes (EPOC) study in relapsing multiple sclerosis
Bruce Hughes et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient Out Comes (EPOC) study in relapsing multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
John P. DiMarco et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
Ludwig Kappos et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Fingolimod phosphate promotes the neuroprotective effects of microglia
Hiromi Noda et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
Stefan Braune et al.
JOURNAL OF NEUROLOGY (2013)
Fingolimod treatment in multiple sclerosis leads to increased macular volume
Rachel Nolan et al.
NEUROLOGY (2013)
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
Marco A. Zarbin et al.
OPHTHALMOLOGY (2013)
Fingolimod protects cultured cortical neurons against excitotoxic death
Luisa Di Menna et al.
PHARMACOLOGICAL RESEARCH (2013)
Initiating oral fingolimod treatment in patients with multiple sclerosis
Barry A. Singer
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2013)
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
Ernst-Wilhelm Radue et al.
ARCHIVES OF NEUROLOGY (2012)
Clinical Pharmacokinetics of Fingolimod
Olivier J. David et al.
CLINICAL PHARMACOKINETICS (2012)
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers
Robert Schmouder et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome
Ruben Deogracias et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Sphingosine-1-Phosphate-Induced Airway Hyper-Reactivity in Rodents Is Mediated by the Sphingosine-1-Phosphate Type 3 Receptor
Alexandre Trifilieff et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Antigen-Specific Adaptive Immune Responses in Fingolimod-Treated Multiple Sclerosis Patients
Matthias Mehling et al.
ANNALS OF NEUROLOGY (2011)
Engagement of S1P1-degradative mechanisms leads to vascular leak in mice
Myat Lin Oo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Impact of sphingosine 1-phosphate modulation on immune outcomes
Daniel D. Pinschewer et al.
NEUROLOGY (2011)
Sphingosine 1-phosphate (S1P) Physiology and the effects of S1P receptor modulation
Timothy Hla et al.
NEUROLOGY (2011)
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
Ji Woong Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
Veronique E. Miron et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Systemic Administration of Sphingosine-1-Phosphate Increases Bronchial Hyperresponsiveness in the Mouse
Fiorentina Roviezzo et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2010)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
N. De Stefano et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Balance of S1P(1) and S1P(2) signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature
Jen-Fu Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2009)
FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
Carolyn A. Foster et al.
BRAIN PATHOLOGY (2009)
Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules
David Marsolais et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Veronique E. Miron et al.
ANNALS OF NEUROLOGY (2008)
S1P(1) receptor signaling overrides retention mediated by G alpha(i)-coupled receptors to promote T cell egress
Trung H. M. Pham et al.
IMMUNITY (2008)
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2008)
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis
Carolyn A. Foster et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors
Rochelle P. Coelho et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis
Balazs Balatoni et al.
BRAIN RESEARCH BULLETIN (2007)
Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors
Florian Mullershausen et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness
Fiorentina Roviezzo et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
Sphingosine 1-phosphate causes airway hyper-reactivity by Rho-mediated myosin phosphatase inactivation
Hiroaki Kume et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation - Novel role for hyaluronan and CD44 receptor family
Patrick A. Singleton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection
Wenhui Hu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
FTY720: Placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects
Robert Schmouder et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo
M. Germana Sanna et al.
NATURE CHEMICAL BIOLOGY (2006)
The measurement and clinical relevance of brain atrophy in multiple sclerosis
RA Bermel et al.
LANCET NEUROLOGY (2006)
The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh
L Koyrakh et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
JR Nofer et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
Sphingosine 1-phosphate-induced vasoconstriction is elevated in mesenteric resistance arteries from aged female rats
DG Hemmings et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Vascular sphingosine-1-phosphate SIP1 and SIP3 receptors
C Waeber et al.
DRUG NEWS & PERSPECTIVES (2004)
Central memory and effector memory T cell subsets: Function, generation, and maintenance
F Sallusto et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2
HP Zhou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
Sphingosine-l-phosphate stimulates contraction of human airway smooth muscle cells
HM Rosenfeldt et al.
FASEB JOURNAL (2003)
Sphingosine 1-phosphate and control of vascular tone
APV Dantas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate
S Salomone et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles differential role in vasoconstriction
F Coussin et al.
CIRCULATION RESEARCH (2002)
Cell type-specific localization of human cardiac S1P receptors
D Mazurais et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells
M Morales-Ruiz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory
DD Pinschewer et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
